BridgeMD
New treatment option for Dysmenorrhea
Official title IV Magnesium in the Treatment of Acute Dysmenorrhea
ClinicalTrials.gov ID: NCT07248540
What this study is testing
What is Magnesium Sulfate (2 Ampoules)?
Magnesium Sulfate (2 Ampoules) is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for dysmenorrhea.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This prospective, randomized, double-blind clinical trial aims to evaluate the analgesic efficacy of intravenous magnesium sulfate in women presenting to the emergency department with acute dysmenorrhea. Participants will be randomized into two groups receiving either 2 ampoules of magnesium sulfate or intravenous dexketoprofen.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 35, women only
You may be able to join if
- Female patients aged 18 to 35 years
- Presenting to the obstetrics and gynecology emergency department with a diagnosis of primary dysmenorrhea
- Having regular menstrual cycles within the last 6 months
- Having a Visual Analog Scale (VAS) pain score of ≥6 at emergency admission
- Providing written informed consent for participation in the study
You likely can't join if
- Patients with secondary dysmenorrhea or underlying gynecological pathology
- Pregnancy or breastfeeding
- Use of analgesics or muscle relaxants within the last 3 days
- Known allergy to magnesium sulfate or dexketoprofen trometamol
- History of renal failure, cardiac arrhythmia, or serious systemic disease
- Inability to assess pain due to mental disability or communication disorder
See the full eligibility criteria
- Female patients aged 18 to 35 years
- Presenting to the obstetrics and gynecology emergency department with a diagnosis of primary dysmenorrhea
- Having regular menstrual cycles within the last 6 months
- Having a Visual Analog Scale (VAS) pain score of ≥6 at emergency admission
- Providing written informed consent for participation in the study
- Patients with secondary dysmenorrhea or underlying gynecological pathology
- Pregnancy or breastfeeding
- Use of analgesics or muscle relaxants within the last 3 days
- Known allergy to magnesium sulfate or dexketoprofen trometamol
- History of renal failure, cardiac arrhythmia, or serious systemic disease
- Inability to assess pain due to mental disability or communication disorder
- Failure to provide informed consent for participation in the study
The study team makes the final eligibility decision.
Where it's taking place
- Gaziosmanpaşa, Outside of the US, Turkey (Türkiye)
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 35 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Gaziosmanpaşa, Outside of the US, Turkey (Türkiye). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.